Share
Eric Benevich
aTyr Pharma, Inc., a clinical-stage biotechnology company developing innovative medicines based on its proprietary tRNA synthetase platform, announced the appointment of Eric Benevich to its Board of Directors.
Mr. Benevich brings over 30 years of commercial leadership experience in the pharmaceutical industry. Since May 2015, he has served as Chief Commercial Officer at Neurocrine Biosciences, Inc., overseeing commercial strategy, marketing, and sales for its product portfolio.
His career includes key leadership roles at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals, where he contributed to the commercialization of therapies such as Prilosec®, Epogen®, Enbrel®, and Neudexta®.
Mr. Benevich holds a BBA in International Business from Washington State University.
